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Abstract
Our National Preparedness Vision requires the U.S. to be prepared to prevent,
protect against, respond to, and recover from all hazards associated with a chemical
attack. Results of this study demonstrate that we cannot protect service members and
first responders as required following a nerve agent attack. The research presented herein
aimed to construct a physiologically based pharmacokinetic model to determine optimal
therapeutic strategies for organophosphate (nerve agent) poisoning. The constructed
model integrated organophosphates and two antidotes, atropine and oximes. Currently,
both antidotes are fielded to military members of all services for medical treatment.
Model results reasonably mirrored literature data and anecdotal observations of
organophosphate poisoning. Results suggest a symptoms-based dosing strategy of
atropine and a time-based dosing strategy of oximes. For patients severely poisoned with
organophosphorus nerve agents, which are to be expected in combat operations, model
results support documented claims of oxime’s inefficacy and tendency to heighten the
severity of poisoning. The results strongly indicate that military personnel attacked with
nerve agents are at a significant health risk if they employ their prescribed treatment as
current doctrine dictates. Results presented herein suggest that oxime use be
discontinued as currently prescribed within the context of nerve agent exposure; its use
will not alter the effects of nerve agent exposure and may increase adverse effects.
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OPTIMIZATION OF THERAPEUTIC STRATEGIES FOR
ORGANOPHOSPHATE POISONING

I. Introduction
Background
In the 1800s, chemists synthesized the first organophosphorus chemical (Szinicz,
2005:173). Researchers later created various forms of the organophosphate and applied
the chemicals as insecticides (Szinicz, 2005:173). In the 1930s, a German chemist
developed exceptionally lethal organophosphates, which were soon applied to weapon
systems and eventually classified as the first nerve agents (Szinicz, 2005:173). Continued
investigation of these chemicals over the past seventy years has produced greater variants
of organophosphorus insecticides and nerve agents (Cannard, 2006:87).
Organophosphates poison an estimated 100,000 people each year throughout the
world (Thiermann and others, 1999:23). The mechanism of poisoning is consistent for all
organophosphate varieties (Szinicz and others, 2007:27). When introduced into the body,
organophosphates bind to acetylcholine esterases at neural synapses (Cannard, 2006:86).
The function of acetylcholine esterases is to hydrolyze neural transmitters, known as
acetylcholine molecules (Cannard, 2006:87). Acetylcholine molecules carry neural
transmissions across synapses from one nerve cell to another nerve cell (Cannard,
2006:87). While acetylcholine esterases are bound to organophosphates, acetylcholine
molecules are not hydrolyzed and are free to repeatedly stimulate the receiving nerve cell
(Cannard, 2006:87). This continuous neural stimulation produces the classic symptoms of
1

organophosphate poisoning, which include, among many, muscle spasms and excess
gland secretion (Cannard, 2006:88). The most severe poisonings can result in respiratory
failure and death (Cannard, 2006:89).
The two widely accepted antidotes for organophosphate poisoning are atropine
and oximes (Cannard, 2006:92). Atropine temporarily binds to neural receptor sites
without initiating neural stimulation (Cannard, 2006:92). Atropine’s competition for the
neural receptor sites reduces acetylcholine molecules’ access to these sites and,
subsequently, dampens excessive neural stimulation (Cannard, 2006:92). Oximes break
organophosphate-acetylcholine esterase bonds (Cannard, 2006:92). Freed acetylcholine
esterases may then resume the hydrolysis of acetylcholine molecules and, consequently,
also dampen excessive neural stimulation (Cannard, 2006:92).
Despite the wide acceptance of these antidotes to mitigate organophosphate
poisoning, various government agencies currently suggest different dosing strategies for
the antidotes (Cannard, 2006:91). Some researchers acknowledge that the optimal dose of
the antidotes is controversial (Heath and McKeown, 2002:24). The conflicting treatment
strategies result from a deficiency in the overall organophosphate research. This research
deficiency has inspired the purpose of this thesis.
Research Objectives
1. Construct a physiologically based pharmacokinetic (PBPK) model to predict the
tissue concentrations of organophosphates, atropine, oximes, and pertinent
biological chemicals.
2. Integrate the reactions among these chemicals into the model and produce a
quantitative measurement of their aggregate effects.
2

3. Apply therapeutic strategies for atropine and oximes against an organophosphate
exposure to the model.
4. Compare model output and report significant differences in therapeutic strategies.
Challenges
Over the past fifteen years, a few researchers have applied PBPK modeling to
predict levels of organophosphates in human tissue. In 1994, Gearhart and others created
the first such PBPK model for two types of organophosphates (Gearhart and others,
1994:1). The researchers provided evidence that a PBPK model for organophosphates
could be adapted for cross-species studies and across the family of organophosphorus
chemicals (Gearhart and others, 1994:12-13). In 2002, Timchalk and others supported
these findings with a similar study on a different organophosphate (Timchalk and others,
2002:42). Also in 2002, Gentry and others conducted a similar study, but the researchers
expanded the utility of the PBPK model to incorporate greater interaction between the
organophosphates and biological chemicals (Gentry and others, 2002:137). However,
none of these studies have fully incorporated the antidotes and their interactions with
other chemicals into the model across all tissue groups. As a result, the proposed research
will require an expansion of the scope and utility of the models presented in literature.
Research literature provides limited information on model parameters and
coefficients for organophosphates and their antidotes. The toxic nature of the chemicals
makes human testing difficult and, in some cases, impossible. In addition, Szinicz and
others suggest that pharmaceutical companies have little motivation to invest in more
detailed research concerning organophosphate poisoning (Szinicz and others, 2007:2324). Therefore, this research must determine some parameters and coefficients that
3

produce model results, which mimic limited observations of organophosphate poisoning
and antidote efficacy.
Furthermore, some researchers question the efficacy of oximes. Animal and in
vitro experiments suggest that oximes are effective, while other reports of
organophosphate poisoned humans suggest oximes are ineffective (Szinicz and others,
2007:25). Szinicz and others acknowledge that “the true efficacy of oximes in patients
with acute organophosphate poisoning is not known” (Szinicz and others, 2007:25). The
researchers suggest that future studies on oximes consider the possibility that
acetylcholine esterases, freed from bonds with organophosphates by oximes, rebind with
“persisting organophosphates in the body” (Szinicz and others, 2007:26).
Finally, the deleterious effects of organophosphate poisoning are numerous, and
the severity of organophosphate poisoning varies across the chemical class (Cannard,
2006:88-89). In addition, the effectiveness of an antidote dose varies with the severity of
organophosphate toxicity (Cannard, 2006:91). This study must aggregate the reactions
among organophosphates, antidotes, and biological chemicals to produce a single,
quantifiable result in order to facilitate comparison among different therapeutic strategies.
Justification and Applicability
Organophosphorus insecticides are one of the most predominant insecticides used
today (Reigart and Roberts, 1999:34). Over forty registered brands of insecticides contain
organophosphorus chemicals (Reigart and Roberts, 1999:34). In 1996, the United States
accounted for more than 4,000 of the yearly organophosphate poisonings experienced
throughout the world (Reigart and Roberts, 1999:5). Since relatively minor poisonings do
not necessarily initiate medical treatment, these numbers are likely an underestimate of
4

actual organophosphate poisonings. Most organophosphate poisonings occur through
association with the agricultural industry by accidental and excessive exposure or by
improper application of insecticides (Calvert and others, 2004:20).
Sarin, soman, tabun, and VX are the most common nerve agents (Cannard,
2006:87). Despite being first developed in the 1930s, it was not until the 1980s, well after
international bodies established protocols to curb use of these chemicals, that the first
employment of nerve agents as a weapon was documented (Szinicz, 2005:172). Iraq
employed tabun and sarin against Iranian military forces between 1983 and 1984 and
between 1987 and 1988 during the Iran-Iraq War (Szinicz, 2005:172). Iraq also employed
sarin against civilian Iraqi Kurds, an ethnic sub-population of Iraq, between 1987 and
1988 (Szinicz, 2005:172).
In 1994, Aum Supreme Truth, a religious cult, synthesized sarin and employed
the chemical against Japanese government agencies and citizens to further the cult’s
political and religious goals (Yanagisawa and others, 2006:76). The terrorist cult released
12 liters of a 70% sarin solution in Matsumoto, Japan (Yanagisawa and others, 2006:77).
The nerve agent killed 7 people and caused 56 hospital inpatient casualties, 208 hospital
outpatient casualties, and 277 on-scene treated sicknesses (Yanagisawa and others,
2006:77). In 1995, the terrorist group again released sarin, this time on the Tokyo
subway, killing 12 people and causing over 500 illnesses, which included 100 first care
responders. (Yanagisawa and others, 2006:81)
The history of organophosphates is disturbing. Despite growing knowledge of the
toxicity of these chemicals and government controls and education efforts to reduce
poisonings, the use of these chemicals and number of annual poisonings remains
5

significantly high. In addition, despite international efforts to control the development,
storage, proliferation, and use of nerve agents, it has not been enough to deter
governments and terrorist organizations from creating and employing these chemicals.
The threat of organophosphate poisoning is genuine and current. A more complete
understanding of organophosphate antidotes could help to more effectively mitigate
symptoms and save lives. The rapid onset of organophosphate induced symptoms and the
chemicals’ potential to quickly cause death, especially from the more toxic
organophosphates, provides motivation to more accurately and decisively define the
dosing strategies for prompt and proper treatment.

6

II. Literature Review
History of Methodology
Since the development of organophosphates, researchers have conducted much
study to better understand the chemicals. In the late 1980s, a subset of the overall
organophosphate research arose that involves the application of physiologically based
pharmacokinetic (PBPK) modeling (Maxwell and others, 1987:66). PBPK models predict
tissue dose concentrations of chemicals in organisms with respect to time (Andersen,
2003:10). The model categorizes human mass into discrete tissue groups with similar
pharmacokinetic properties (Andersen, 2003:12). Modelers create mass balance
differential equations around each tissue group (Andersen, 2003:11). Equation
parameters include tissue volumes, blood flow rate, breathing rate, metabolic constants,
and unique chemical characteristics (Andersen, 2003:12). The modeling tool numerically
integrates the equations to determine the chemical amounts in the tissue over time
(Andersen, 2003:11).
PBPK modeling is predominantly used to predict human tissue concentrations of
a chemical by inferring data from laboratory experiments conducted on animals
(Andersen, 2003:13-14). In general, this method gains data from test animals, applies the
data to a PBPK model, adjusts the model to simulate experimental results, and then
applies human parameters to the model in place of animal parameters to predict human
results (Andersen, 2003:13-14). Modelers then repeatedly execute the human model over
a wide range of scenarios that were not studied in the laboratory experiment (Andersen,
7

2003:10). Not only does this technique save time and money, but it also allows
researchers to obtain human results when human experiments are impossible or severely
limited due to the toxicity of the chemical (Andersen, 2003:14). In addition, the modeling
technique allows researchers to obtain results for humans exposed to low dose
concentrations of a chemical over decades from data obtained through laboratory
experiments on animals exposed to high dose concentrations of a chemical over days or
weeks (Andersen, 2003:10).
Another valuable application of PBPK modeling is to create a hypothesis for a
future laboratory experiment based on the results of the model, which was created from
the current understanding of physiology and the chemicals under study (Andersen,
2003:14). This technique is particularly useful when physiological mechanisms and
chemical interactions are vaguely understood or are unproved and when historical data
are limited. A successful model will predict future results of laboratory experiments and
help provide evidence to support understood mechanisms (Andersen, 2003:14). However,
and ironically, an unsuccessful model, which fails to predict future laboratory results, is
likely more useful in that it initiates rigorous questioning of understood mechanisms.
This rigorous questioning may lead to insights and greater understanding of a chemical
and its interactions with physiology (Andersen, 2003:14).
The application of PBPK modeling for organophosphates began in 1988 with a
study by Maxwell and others (Maxwell and others, 1988:66). The researchers dosed rats
with 90 μg/kg of soman and measured tissue concentrations of the organophosphate and
acetylcholine esterase inhibition (Maxwell and others, 1988:68). These measurements
were used to determine any correlation among the organophosphate tissue concentration,
8

esterase inhibition, and physiological parameters (Maxwell and others, 1988:67).
Maxwell and others found a strong correlation between esterase inhibition and blood
flow, a key component of PBPK modeling (Maxwell and others, 1988:69-72). As a
result, the researchers suggested “that it may be possible to use a flow-limited
physiological pharmacokinetic model to describe the kinetics of in vivo esterase
inhibition by soman” (Maxwell and others, 1988:66).
In 1994, Gearhart and others tested Maxwell’s suggestion. The researchers
determined “to develop a quantitative, physiologically based model for organophosphate
pharmacokinetics and acetylcholine esterase inhibition” (Gearhart and others, 1994:3).
The researchers dosed rats with the organophosphate, diisopropylfluorophosphate (DFP),
and measured tissue concentrations of the organophosphate and esterase activity
(Gearhart and others, 1994:5). The researchers then constructed a model and optimized
parameters until the model simulated the experimental data (Gearhart and others, 1994:56). Next, the researchers applied human parameters to the model (Gearhart and others,
1994:5-6). Model results for the human reasonably mirrored DFP data obtained from
literature concerning DFP therapeutic treatments (Gearhart and others, 1994:13).
Furthermore, the researchers then adapted the model to another organophosphate,
parathion (Gearhart and others, 1994:13). Again, the model results reasonably mirrored
literature data (Gearhart and others, 1994:13). The researchers provided evidence that the
PBPK model could predict tissue concentrations of organophosphates, that the model was
applicable for cross-species studies, and that the model was applicable across the family
of organophosphorus chemicals (Gearhart and others, 1994:12-13).
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In 2002, Timchalk and others created a similar PBPK model for chlorpyrifos
(CFP), a less lethal organophosphate, which is used in insecticides (Timchalk and others,
2002:34). The researchers fed rats with CFP and measured tissue concentrations of CFP
over time (Timchalk and others, 2002:35). Using the experimental data, literature data,
and optimization techniques, the researchers successfully constructed a model that
produced results that mirrored the experiment (Timchalk and others, 2002:35). The
researchers then applied human parameters to the model (Timchalk and others, 2002:41).
As with the study by Gearhart and others, the model reasonably mirrored experimental
data obtained from human testing from another study (Timchalk and others, 2002:42).
Again, more evidence supported PBPK modeling of organophosphates (Timchalk and
others, 2002:42).
In 2002, Gentry and others created a similar PBPK model for the
organophosphate, parathion, and its metabolite, paraoxon (Gentry and others, 2002:120).
The researchers intended to provide an estimate on how polymorphism affects tissue
doses and toxicity of a chemical (Gentry and others, 2002:120). Although the results of
the experiment showed that the genetic variations had little effect on the toxicity of
parathion, the study did further provide evidence for applying PBPK modeling to
determine tissue concentrations of organophosphates (Gentry and others, 2002:131). In
addition, the researchers were able to expand the utility of the model by incorporating
greater interaction between the organophosphate and biological chemicals (Gentry and
others, 2002:125-137).
PBPK modeling is highly dependent upon the mechanisms of the cardiovascular
system. Organophosphates and their antidotes interact extensively with the nervous
10

system. To facilitate a more detailed explanation of the mechanisms of the chemicals and
PBPK modeling, the next two sections will provide a brief review of the cardiovascular
and nervous systems.
Cardiovascular System
The cardiovascular system consists of the heart and a network of closed loop
blood vessels (Fox, 2006:382). Arteries transport blood away from the heart and veins
return blood to the heart (Fox, 2006:382). Capillaries are smaller and more numerous
vessels that connect arteries and veins in tissue (Fox, 2006:406).
Blood consists of erythrocytes, leukocytes, and platelets, which are suspended in
plasma (Fox, 2006:384-385). Plasma is predominantly water and solutes (Fox, 2006:383).
An important function of the cardiovascular system is to carry nutrients, waste,
and other chemicals to and from tissue (Fox, 2006:382). All transfer of materials to and
from the blood and tissue occurs across capillary walls (Fox, 2006:382-383). The human
body consists of more than 40 billion capillaries that provide nearly 1000 square miles of
surface area for diffusion of chemicals between blood and tissue (Fox, 2006:408). Nearly
every cell in the human body is within 60 to 80 μm of a capillary (Fox, 2006:408).
Blood pressure drives water and solutes from the plasma through capillary walls
into interstitial fluid at the arterial end of capillaries (Fox, 2006:431). As blood pressure
drops at the venous end of the capillaries, concentration gradients will drive some
amounts of water and solutes from the interstitial fluid back into the capillaries (Fox,
2006:432).
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Figure 1. Capillary Diffusion (Fox, 2006:431-432)
Nervous System
Motor neurons are classified as somatic or autonomic (Fox, 2006:156). Somatic
motor neurons direct the reflexive and voluntary control of skeletal muscles (Fox,
2006:156). Originating in the central nervous system (CNS), somatic neurons extend into
the peripheral nervous system (PNS) and terminate at receptors of skeletal muscles (Fox,
2006:156). Autonomic motor neurons are located in the PNS (Fox, 2006:156).
Autonomic neurons receive neural transmission from other neurons extending from the
CNS and relay the neural transmission to receptors of involuntary tissues: smooth
muscles, cardiac muscle, and glands (Fox, 2006:156).
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Figure 2. Central and Peripheral Nervous System (adapted from Fox, 2006:156)
An approximately 10 nm wide cleft, called a synapse, separates neurons from
other neurons, muscles, and glands (Fox, 2006:172). Adhesion molecules that project
from both sides of the synapse hold the width of the cleft constant. (Fox, 2006:171)
Neural transmission across synapses of motor neurons is one-way, in the direction from
the CNS to the receptor, and occurs with the release of neurotransmitters from the presynaptic neuron and the reception of neurotransmitters by the post-synaptic cell (Fox,
2006:172). Acetylcholine molecules are the most common neurotransmitters in the body
and the ones indirectly affected by organophosphate poisoning (Fox, 2006:175).
The pre-synaptic neuron contains small sacs, which store acetylcholine molecules
(Fox, 2006:172). Upon neural stimulation, the sacs fuse with the membrane of the presynaptic neuron and create pores through which the acetylcholine molecules diffuse into
the synaptic cleft (Fox, 2006:172). The amount of acetylcholine molecules released into
the cleft is dependent on the amount of acetylcholine molecules in the sac, the number of
sacs fusing to the membrane, and the frequency of neural transmission (Fox, 2006:172).
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Some of the sacs are pre-staged at the pre-synaptic nerve cell membrane to increase the
speed of neural transmission (Fox, 2006:172).

Figure 3. Acetylcholine Structure (Rand, 2007:116)
Once in the cleft, acetylcholine molecules diffuse across the synapse through
interstitial fluid and briefly bind to receptor sites on the post-synaptic cell (Fox,
2006:173-177). It is these binds between acetylcholine molecules and the post-synaptic
receptor sites that stimulate the neural functioning of the post-synaptic cell (Fox,
2006:173). After a short time, acetylcholine molecules will disassociate from the
receptor sites and maintain the potential to re-bind to the receptors (Fox, 2006:177).
There are two types of cholinergic receptors that receive acetylcholine molecules:
nicotinic receptors and muscarinic receptors (Fox, 2006:174-175). Nicotinic receptors are
found between neurons and skeletal muscles, between neurons and non-voluntary
muscles, and between some neurons and other neurons in the CNS (Fox, 2006:174).
Muscarinic receptors are found between neurons and glands in the PNS and also between
some neurons and other neurons in the CNS. (Fox, 2006:175)
Acetylcholine esterases are enzymes embedded on the post-synaptic cell and
which terminate the action of acetylcholine molecules (Fox, 2006:177). The serine
hydroxyl group of the acetylcholine esterase binds to the acetyl portion of the
acetylcholine. With this bind, the choline moiety of the acetylcholine is released
14

(Cannard, 2006:87). Hydrolysis then separates the acetyl moiety from the acetylcholine
esterase (Cannard, 2006:87). The choline moiety will return to the pre-synaptic cell to be
recycled for the creation of new acetylcholine, while the acetyl group will react with
water to form acetic acid (Cannard, 2006:87). Acetylcholine esterases are extremely
effective and each enzyme has the potential to hydrolyze 300,000 acetylcholine
molecules per minute (Hoskins and Ho, 1992:289). Acetylcholine esterases are the only
enzymes that hydrolyze acetylcholine. Without acetylcholine esterases, acetylcholine
molecules will persist in the synaptic cleft, continually bind and disassociate with
receptor sites, and cause excessive neural stimulation (Fox, 2006:178).

Figure 4. Synaptic Cleft (adapted from Fox, 2006:178)
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Organophosphates
Organophosphates are liquid chemicals (Cannard, 2006:87). An organophosphate
is characterized by central phosphorous atom bound to an oxygen atom, two alkyl groups,
and a leaving group (Cannard, 2006:87). Although liquid, organophosphates are,
generally, easily volatized (Cannard, 2006:87). As a result, the most likely human
exposure to organophosphates is through inhalation, although intake of the chemicals
through dermal absorption or ingestion is possible (Cannard, 2006:87).

Figure 5. Organophosphate Structure (Cannard, 2006:87)
Regardless of the entry route into the body, organophosphates will diffuse into the
blood stream, and the cardiovascular system will transport the chemicals to all tissue
groups. In the tissue groups, organophosphates will move towards neural synapses and
bind to acetylcholine esterases (Cannard, 2006:87). After a period of time, which is
different for each organophosphate type, the organophosphate-esterase bonds will mature
by the de-alkylation of the organophosphates (Cannard, 2006:87). Upon maturation, the
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organophosphate-esterase bonds will become irreversible and both the organophosphates
and acetylcholine esterases are destroyed. (Cannard, 2006:87)
When acetylcholine esterases are bound to organophosphates, acetylcholine
molecules are not hydrolyzed, accumulate in the synapse, and cause over-stimulation of
the nervous system (Cannard, 2006:87). This over-stimulation leads to a variety of
physiological effects, which are dependent on the type of neural receptor and location in
the body (Cannard, 2006:88-89).
In the PNS, over stimulation of muscarinic receptors causes continuous
contraction of smooth muscles and secretion of exocrine glands (Cannard, 2006:88).
Effects include “miosis with dim or blurred vision, eye pain (ciliary spasm) or headache,
tearing, rhinorrhea, salivation, bronchoconstriction and excessive bronchosecretions with
dyspnea, bradyarrhythmias, hypotension, nausea and vomiting, abdominal cramps,
diarrhea and bowel incontinence, and urinary incontinence” (Cannard, 2006:88). Also in
the PNS, organophosphates lead to the over-stimulation of nicotinic receptors causing
uncontrolled contraction of voluntary muscles (Cannard, 2006:87).
Both muscarinic and nicotinic receptors are found in the CNS (Fox, 2006:156).
In the CNS, over-stimulation of both receptor types causes “mild to severe behavioral and
cognitive changes, impaired consciousness or coma, seizures, or central apnea” (Cannard,
2006:89). If the exposed person survives the initial effects of organophosphate
poisoning, other symptoms may persist for weeks and include “irritability, anxiety,
depression, fatigue, insomnia, nightmares, and impaired judgment” (Cannard, 2006:89).
The only way to terminate the effects of organophosphate poisoning is the
elimination of the organophosphates from the body and the full recovery of acetylcholine
17

esterases (Cannard, 2006:87). Destruction of the organophosphates is relatively quick via
natural metabolic degradation. However, the recovery of acetylcholine esterases is
relatively slow (Cannard, 2006:87). Effects from organophosphate poisoning can persist
for weeks as a result of deficient acetylcholine esterases in tissue groups and not from
organophosphate persistence in the body (Cannard, 2006:89).
Four naturally occurring chemicals in the body will destroy organophosphates
(Gearhart and others, 1994:4). At the neural synapse, acetylcholine esterases initiate the
release of the organophosphates’ leaving group and the destruction of the
organophosphates upon bond maturation (Cannard, 2006:87).
In addition to being found in tissue groups, butyrylcholinesterases and other
acetylcholine esterases are found in the blood stream and have the first opportunity to
attach to organophosphates (Cannard, 2006:86). Like organophosphate-acetylcholine
esterase bonds, organophosphate-butyrylcholinesterase bonds become irreversible with
maturation, and the butyrylcholinesterases and organophosphates are destroyed with the
separation of the organophosphates’ leaving group (Gearhart and others, 1994:4). Unlike
acetylcholine esterases, the loss of butyrylcholinesterases to organophosphate poisoning
appears to have no imminent effect on life sustaining functions (Cannard, 2006:88).
Carboxylesterases are found throughout the body and in much greater numbers
than acetylcholine esterases and butyrylcholinesterases. These enzymes also bind to and
mature with organophosphates (Gearhart and others, 1994:4). As with
butyrylcholinesterases, there is no known adverse physiological affect from the loss of
carboxylesterases.
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The enzyme suite, cytochrome P450, metabolizes organophosphates. (Levi and
Hodgson, 1992:142). Elements of this enzyme suite are found in all tissue groups except
fat tissue (Gearhart and others, 1994:3).
Antidotes
There are three widely accepted medications to treat organophosphate poisoning.
The first medication, oxime, is introduced into the body intravenously or intramuscularly
(Cannard, 2006:92). Oximes will attack the organophosphate-esterase bonds and
separate the chemicals (Cannard, 2006:92). However, oximes are only effective prior to
maturation of the organophosphate-esterase bonds (Cannard, 2006:92). For reference,
the maturation half-time of soman is 2-6 minutes, while the maturation half-time for
tabun, sarin, and VX is between 5 and 48 hours (Cannard, 2006:92). Esterases are fully
recovered and operational with effective separation from the organophosphates (Cannard,
2006:92). However, oximes appear to “have little effect on muscarinic symptoms and
signs” (Cannard, 2006:92). There are a few varieties of oximes, but they all operate in
essentially the same manner (Cannard, 2006:92). The U.S. uses Pralidoxime Chloride (2Pam Cl) (Cannard, 2006:92).
Atropine may also be introduced into the body intravenously or intramuscularly
(Cannard, 2006:92). At muscarinic receptors only, atropine will repeatedly bind to and
dissociate with the neural receptors without causing neural stimulation (Cannard,
2006:92). The presence of atropine will reduce the availability of muscarinic receptors to
acetylcholine molecules (Cannard, 2006:92). As a result, atropine will reduce the
excessive secretion of exocrine glands and the over-stimulation of smooth muscles
(Cannard, 2006:92). The body will naturally metabolize or excrete atropine over time.
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At high doses, atropine can cause adverse health effects (USAMRICD,
2000:120). Generally, people not exposed to organophosphates with doses of 10 mg of
atropine or higher may experience delirium (USAMRICD, 2000:120). In addition, the
blockage of neural receptors at glands may inhibit sweating and endanger an individual to
heat related injuries (USAMRICD, 2000:120). Furthermore, small amounts of atropine
can cause blurred vision for up to a day (USAMRICD, 2000:123).
The third medication for organophosphate poisoning is an anticonvulsant, and
diazepam is the preferred medicine (Cannard, 2006:92). Diazepam reduces the severity
of seizures and epilepsy, which are caused by over-stimulation of muscarinic and
nicotinic receptors in the CNS (Cannard, 2006:92-93). This medication will not be
studied in the model.
Therapeutic Strategies
Therapeutic strategies vary among government agencies (Cannard, 2006:91). The
Centers for Disease Control and Prevention (CDC) base initial dosing procedures on
observations of symptoms (CDC, 2008:13). The symptoms are classified as either mildmoderate or severe (CDC, 2008:13). “Mild-moderate symptoms include localized
sweating, muscle fasciculations, nausea, vomiting, weakness, and dyspnea” (CDC,
2008:13). For adults with these symptoms, first care responders are directed to initially
administer one or two atropine injections of 2 mg each and one 2-Pam Cl injection of 600
mg (CDC, 2008:13). Additional atropine doses are repeated every 5 to 10 minutes (CDC,
2008:13). There are no instructions to first care responders for repeated doses of 2-Pam
Cl. Both atropine and 2-Pam Cl injections are administered intramuscularly by first care
responders (CDC, 2008:13).
20

“Severe symptoms include unconsciousness, convulsions, apnea, and flaccid
paralysis” (CDC, 2008:13). For adults, first care responders are directed to administer
three atropine injections of 2 mg each (CDC, 2008:13). Additional atropine injections of
2 mg should be administered “at 5 to 10 minute intervals until secretions have diminished
and breathing is comfortable or airway resistance has returned to normal” (CDC,
2008:13). Eighteen hundred mg of 2-Pam Cl are administered with the initial atropine
injection. (CDC, 2008:13). As with mild to moderate symptoms, there are no instructions
for additional doses of 2-Pam Cl (CDC, 2008:13).
Medical doctors with appropriate equipment are provided slightly different
instructions (CDC, 2008:19). The procedure for administering atropine is identical to the
instructions provided to first care responders (CDC, 2008:19). However, medical doctors
will slowly administer 15 mg/kg of 2-PAM Cl intravenously for mild-moderate and
severe symptoms (CDC, 2008:19). In addition, medical doctors may administer 5 mg of
diazepam intravenously for patients with convulsions (CDC, 2008:19).
The New York Department of Health (NYDH) provides slightly different
procedures for first care responders (NYDH, 2008:4). For mild to moderate symptoms, 2
to 4 mg of atropine and 600 mg of oxime are administered intramuscularly (NYDH,
2008:4). For severe symptoms, 6 mg of atropine and 1800 mg of oxime are administered
intramuscularly (NYDH, 2008:4). For all cases, unspecified amounts of atropine are
repeated every 2 to 5 minutes until breathing has returned to near normal (NYDH
2008:4). Unspecified amounts of 2-Pam Cl are repeated once between 30 to 60 minutes
and then 1 to 2 doses every hour thereafter (NYDH, 2008:4).
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Yet again, the U.S. Army Medical Research Institute of Chemical Defense
(USAMRICD) provides slightly different instructions (USAMRICD, 2008:123-125). For
mild symptoms, 2 mg of atropine and 600 mg of 2-Pam Cl are administered
(USAMRICD, 2008:123-124). For severe symptoms, 6 mg of atropine and 1800 mg of 2Pam Cl are administered (USAMRICD, 2008:124). Additional doses of 2 mg of atropine
are repeated every three to five minutes until breathing is near normal (USAMRICD,
2008:123-124). There are no instructions for administering additional doses of 2-Pam Cl
(USAMRICD, 2008:124).
Finding the correct dosage of atropine is difficult (USAMRICD, 2008:124). There
is a risk of giving too much atropine to a patient experiencing mild symptoms, and
therefore, produce adverse effects on the patient from the atropine (USAMRICD,
2008:124). In addition, there is a risk of giving too little atropine to a patient with severe
symptoms, and experience the risk of not properly treating the patient (USAMRICD,
2008:124).

Atropine

2-Pam Cl

Table 1. Therapeutic Strategies for Mild to Moderate Symptoms
CDC
NYPH
USAMRICD
Initial Dose
2 – 4 mg
2 – 4 mg
2 mg
Repeat Dose
2 mg
Unspecified
2 mg
Repeat Interval 5 – 10 min
2 – 5 min
3 – 5 min
Initial Dose
600 mg
600 mg
600 mg
Repeat Dose
No Instructions 600 – 1200 mg
No
Instructions
Repeat Interval No Instructions Once b/w 30 – 60
No
min
Instructions
& every hr
thereafter
(CDC, 2008:13; NYDH, 2008:4; USAMRICD 2008:124)
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Atropine

2-Pam Cl

Table 2. Therapeutic Strategies for Severe Symptoms
CDC
NYPH
Initial Dose
6 mg
6 mg
Repeat Dose
2 mg
Unspecified
Repeat Interval 5 –10 min
2 – 5 min
Initial Dose
1800 mg
1800 mg
Repeat Dose
No Instructions 600 – 1200 mg
Repeat Interval

No Instructions

USAMRICD
6 mg
2 mg
3 – 5 min
1800 mg
No
Instructions
No
Instructions

Once b/w 30 –60
min & every hr
thereafter
(CDC, 2008:13, NYDH, 2008:4, USAMRICD 2008:124)

Physiologically Based Pharmacokinetic Modeling
PPBK modeling describes the tissue-dose concentrations of a chemical with
respect to time (Andersen, 2003:10). A mass balance concept is applied to the model to
describe absorption, distribution, metabolism and excretion of chemicals (Hoang,
2003:99). Absorption, or entry, of a chemical into the model is primarily described by
inhalation, dermal absorption, or ingestion (Hoang, 1995:101). Chemical excretion from
the model occurs by metabolizing the chemical into an irrelevant metabolite, loss of the
chemical in whole with urine, or volatilization of the chemical from the blood into the
lungs (Hoang, 1995:102).
Within the model, the entire mass of the organism under study is grouped into
discrete tissue compartments with similar physiological and pharmacokinetic properties
(Hoang, 1995:101). Mass balance equations are created for each compartment to
describe the concentration of the chemical in those compartments with respect to time
(Hoang, 1995:101).
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Figure 6. Basic PBPK Schematic (Gearhart and others, 1994:4)
Distribution of the chemical throughout the model occurs via the blood flow. The
product of the fraction of blood flowing into each compartment, the concentration of the
chemical in the blood (mass/volume), and the cardiac output (volume/time) determines
the amount of chemical entering the compartment (mass/time).
Absorption of the chemical from the blood into the tissue compartment assumes a
lumped-parameter approach (Hoang, 1995:101). In this assumption, the chemical
completely diffuses from the blood into the tissue compartment and instantaneously
achieves a homogenous and well-mixed state throughout the interstitial fluid of that
compartment (Hoang, 1995:101).
A partition coefficient is used to describe the diffusion of the chemical from the
tissue compartment into the venous blood flow. The amount of chemical leaving a
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compartment (mass/time) is equal to the product of the fraction of blood flow from the
compartment, the cardiac output (volume/time), the concentration of the chemical in the
tissue compartment (mass/volume), and the inverse of the partition coefficient. A higher
partition coefficient causes a slower outflow of the chemical from the compartment as
compared to a lower partition coefficient.
Within each compartment, binding and bio-transformation of the chemical will
affect the net accumulation rate of the chemical (Hoang, 1995:101). For example,
mathematical equations are created to describe the alteration of chemicals to irrelevant
byproducts through reaction with other chemicals and enzymes (Hoang, 1995:101).
PBPK modeling relies on pharmacokinetic data from laboratory experiments
(Hoang, 1995:100). Typically, laboratory data are not complete (Hoang, 1995:100).
Unknown parameters and metabolic constants are often determined or estimated through
model fitting (Hoang, 1995:100).
Chemical Reactions
One of the common chemical reactions that occur in the compartments of PBPK
models is the metabolism of a chemical by an enzyme to an irrelevant metabolite (Hoang,
1995:102). This chemical reaction is typically described as follows.
k3
k1
Enzyme + Substrate <-> Enzyme-Substrate Complex -> Enzyme + Product
k2
The chemical reaction can be mathematically expressed according to equation (1)
(Clark, 1996:446).
d[Enzyme-Substrate Complex]/dt = k1[Enzyme][Substrate]
– k2[Enzyme-Substrate Complex]
– k3[Enzyme-Substrate Complex]
25

(1)

Equation (1) is usually simplified to equation (2) (Clark, 1996:446-448).
d[Enzyme-Substrate Complex]/dt = (Vmax[Substrate])/(Km + [Substrate] (2)
Equation (2) is particularly useful since the coefficients, Vmax and Km, for this
formula are found for many chemicals in literature. It is important to note that the enzyme
is not destroyed in this reaction. This chemical reaction is applicable to the cytochrome
P450 metabolism of organophosphates, atropine, and oximes. For reactions between
organophosphates and esterases, the chemical reaction and equation (2) are not
applicable. Esterases are destroyed with bond maturation. Hence the chemical reaction
between organophosphates and esterase is more accurately expressed as follows.
k3
k1
Enzyme + Substrate <-> Enzyme-Substrate Complex -> Aged Enzyme-Substrate
k2
The chemical reaction is mathematically expressed according to equation (1) and
cannot be simplified.
Literature Data
Gearhart and others first applied PBPK modeling to organophosphates (Gearhart
and others, 1994:1). Much of the basic model structure and data were incorporated into
many of the organophosphate PBPK models found in literature that followed. In their
study, Gearhart and others provided human physiological data such as body weight,
ventilation rate, cardiac output, organ volumes, and fraction of blood flows to tissue
groups (Gearhart and others, 1994:5). In addition, the researchers provided the partition
coefficients and metabolic constants for the organophosphate, DFP (Gearhart and others,
1994:3-6). These values are listed in Appendix B.
26

Gentry and others investigated the effects of polymorphisms on the metabolism of
parathion (Gentry and others, 2002:120). To conduct their study, the researchers needed
to incorporate the kinetics between organophosphates and esterases into their model
(Gentry and others, 2002:127-128). Initial concentration, synthesis constants, and
degradation constants for the esterases were obtained from literature data, experiment,
and model fitting. The constants were useful for this study and are listed in Appendix B.
In 2004, Ashani and Pistinner constructed a PBPK model to determine the use of
exogenous butyrylcholinesterases as a prophylactic to protect against organophosphate
poisoning (Ashani and Pistinner, 2004:358). Their model was based on the concept that
free butyrylcholinesterases in the blood stream had the first opportunity to react with
organophosphates (Ashani and Pistinner, 2004:359). If enough butyrylcholinesterases
were present in the blood stream, then much of the organophosphate would react with
butyrylcholinesterases before the organophosphate could enter tissue groups and destroy
acetylcholine esterases in those tissue groups (Ashani and Pistinner, 2004:359).
Furthermore, because butyrylcholinesterases have a higher affinity for organophosphates
as compared to acetylcholine esterases, exogenous butyrylcholinesterases would
additionally protect some levels of acetylcholine esterases in the blood (Ashani and
Pistinner, 2004:365). In their study, the researchers showed that between 48% and 68%
of organophosphates were degraded in plasma before they ever reacted with esterases in
tissue (Ashani and Pistinner, 2004:364). In addition, Ashani and Pistinner postulated with
other researchers that acetylcholine esterase inhibition in tissue “should be well above
65% to produce visible signs” of symptoms and that enzyme inhibition down to 10% of
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basal levels may still permit critical physiological functions (Ashani and Pistinner,
2004:365).
In 1985, Hinderling and others conducted a study to determine the
pharmacokinetics of atropine (Hinderling and others, 1985:703). In two separate tests, the
researchers intravenously dosed three human males with 1.35 and 2.15 mg of atropine
(Hinderling and others, 1985:704). Plasma and urine levels of atropine and the atropine’s
metabolite, tropine, were measured with a gas chromatographic mass spectrometry
(Hinderling and others, 1985:703). The researchers determined that 57% of atropine was
not metabolized and eliminated in whole in the urine (Hinderling and others, 1985:703).
A report for the International Program on Chemical Safety Evaluation in 2002
provides a summary of atropine studies (Heath and McKeown, 2007:1). The authors,
Heath and McKeown, acknowledged that there is little understanding of the “optimal
dose and pharmacokinetics of atropine in relation to the doses of oximes, the severity of
(organophosphate) poisoning, and the properties of a particular organophosphate” (Heath
and McKeown, 2007:30). In their report, the authors cited a study by Schoene and others
that showed pre-dosing rats with atropine before the onset of organophosphate exposure
reduced morality rates for the rats (Heath and McKeown, 2007:15). The authors cited
another study by Matsubara and Horikoshi that suggested atropine alone was more
effective than 2-Pam Cl in treating organophosphate poisoning (Heath and McKeown,
2007:17). The authors further cited an additional experiment by Gupta, who dosed
buffalo calves with an organophosphate, atropine, and 2-Pam Cl (Heath and McKeown,
2007:17). Gupta suggested that a therapeutic strategy of atropine and 2-Pam Cl in
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conjunction was more effective than either antidote working alone (Heath and McKeown,
2007:17).
Heath and McKeown also reported on a study that stated atropine reaches a peak
level in plasma at about 30 minutes after the administration of atropine (Heath and
McKeown, 2007:22). Another study reported that only 5% of atropine remains in the
blood after 5 minutes following an intravenous injection (Heath and McKeown,
2007:23). A third study showed that atropine’s “initial distribution half-life is
approximately one minute.” (Heath and McKeown, 2007:23).
Heath and McKeown point out the complications and difficulties in determining
the optimal dose of atropine for organophosphate poisoning (Heath and McKeown,
2007:24). Numerous case studies show the need for atropine doses ranging from 2 mg to
as high as 50 mg, and some doses as much as 30,000 mg, over a period of 3 weeks (Heath
and McKeown, 2007:24-25). Ultimately, the amount of atropine is determined by the
observation of organophosphate induced symptoms (Heath and McKeown, 2007:26).
Little data is available for oximes and the antidote’s efficacy is in question.
Szinicz and others reviewed and reported some of the complications of this antidote in a
2007 paper (Szinicz and others, 2007:23). The researchers cited studies that confirm the
efficacy of oximes for “in vitro and animal experiments” (Szinicz and others, 2007:25)
However, “human reports of severe toxicity frequently mention the failure of oxime
therapy and conclude oximes to be ineffective, or even harmful.” One of the suggestions
for the failure of the oximes is that there is “re-inhibition of the reactivated enzyme by
persisting organophosphates” in the body (Szinicz and others, 2007:26). The researchers
suggest that future studies consider the total net effect of organophosphates and oximes
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and consider “the various interactions between inhibitor, reactivator, and acetylcholine
esterases” (Szinicz and others, 2007:26).
In a 1999 article, Thiermann and others presented and discussed the numerous
chemical interactions among organophosphates, oximes, and enzymes (Thiermann and
others, 1999:234). The researchers suggested that these chemical reactions can be
expressed mathematically with reaction rate constants (Thiermann and others, 1999:234).
In 2007, Bartling, Worek, Szinicz, and Thiermann investigated the reactions
between organophosphates and esterases (Bartling and others 2007:166). In their article
the researchers provided chemical kinetic rate constants for several organophosphates,
which proved useful for the work presented in this thesis (Bartling and others, 2007:169).
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III. Methodology
Modeling Tool
Model construction and numerical integration was performed with the computer
software, STELLA, version 8.0, developed by High Performance Systems Inc.
Model Structure
The model structure describing absorption, distribution, metabolism, and
excretion was heavily based on physiological mechanisms and the model developed by
Gearhart and others (Gearhart et. al. 1994:4). The basic model structure is depicted in
Figure 7. The model neglected volume and mass of pulmonary tissue; however, a
pulmonary compartment was created to describe pulmonary functions.

Figure 7. Model Structure
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The model described organophosphate absorption by inhalation and described
atropine and oxime absorption by bolus intramuscular injections in the thigh tissue. The
model described chemical distribution by blood flow and described chemical excretion
by loss with urine in the kidney compartment. Natural synthesis and degradation of
esterases and acetylcholine molecules occurred solely within the compartments.
Chemical reactions among organophosphates, esterases, acetylcholine molecules,
atropine, and oximes occurred within each compartment. However, esterase
concentrations were assumed to be negligible or non-existent in fat tissue, and therefore,
no chemical reactions occurred in the fat compartment.
Metabolism of organophosphates occurred by unspecified enzymes in all
compartments except the fat compartment. In addition, degradation of organophosphates
and esterases occurred by maturation of organophosphate-esterase bonds.
Equations
A complete list of equations is provided in Appendix A. All equations for
absorption, distribution, metabolism, and excretion were primarily based on concepts
used by Gearhart and others. All equations for chemical reactions were based on concepts
presented by Clark.
Equation (3) describes the general inflow and outflow of organophosphates,
atropine, and oximes for each compartment.
Accumulation = Inflow + Intramuscular Injection – Outflow
– Metabolism – Urinary Excretion

32

(3)

Natural synthesis and degradation of esterases occurred solely within the
compartments and were described according to equation (4). Esterase levels were
increased by a zero-order synthesis and decreased by first-order degradation.
Esterase Level = Synthesis Constant
– Degradation Constant * Enzyme Concentration

(4)

Chemical reactions between organophosphates and esterases were modeled
according to the following chemical reaction.
l3
l1
Esterase + OP <-> Esterase-OP Complex -> Aged Esterase-OP
l2
The chemical reaction was mathematically expressed according to equation (5).
d[Esterase-OP]/dt = k1[Esterase][OP] - k2[Esterase-OP]
– k3[Esterase-OP]

(5)

Chemical reactions between organophosphate-esterase complexes and oximes
were based on the following chemical reaction.
o1
Esterase-OP + Oxime -> Esterase + OP + Oxime
The chemical reaction was mathematically expressed according to equation (6).
-d[Esterase-OP]/dt = o1[Esterase-OP][Oxime]

(6)

The model described a homeostatic condition of acetylcholine molecules at the
binding sites with acetylcholine esterases. This condition represented one mole of
acetylcholine molecules for every mole of acetylcholine esterases in each tissue
compartment, except the fat compartment. The homeostatic condition was represented by
a zero-order binding rate of acetylcholine molecules to acetylcholine esterases and a
second-order hydrolysis of acetylcholine molecules by acetylcholine esterases.
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d[ACh-AChE]/dt = p1 – p2[AChE][ACh-AChE]

(7)

Atropine does not directly interact with organophosphates or biological
chemicals. Instead it reacts only with the neural receptor sites and limits acetylcholine’s
access to these sites. A simple ratio was incorporated into equation (7) that dampens the
inflow of acetylcholine molecules to the binding sites and thereby integrates the effects of
atropine.
d[ACh-AChE]/dt = p1{p1/( p1 + [Atropine])} - p2[AChE][ACh-AChE]

(8)

Equation (8) simplifies to equation (7) when no atropine is present. In this
situation, the amount of acetylcholine molecules flowing into the binding sites is normal.
If atropine is introduced, the net rate of acetylcholine molecules binding to acetylcholine
esterases is reduced. If acetylcholine esterase levels drop as a result of chemical reactions
with organophosphates, the outflow of acetylcholine molecules from equation (8) is
dampened and results in a net increase of acetylcholine molecules at the binding sites.
Symptoms were described as a ratio between the amount of acetylcholine
molecules at the acetylcholine binding sites and the basal level of acetylcholine
molecules at the binding sites. This quantitative representation of symptoms was used as
the primary index to compare therapeutic strategies.
dSymptoms/dt = [ACh-AChE site]/[Basal ACh-AChE site]

(9)

Assumptions
The model structure and the physiological mechanisms it is based on are drawn
from current understanding of physiology, biological chemicals, organophosphates, and
antidotes. Many of these mechanisms are vaguely or incompletely understood. In
addition, the model attempts to simplify mechanisms where possible. Furthermore, much
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pharmacokinetic data is incomplete for these chemicals. Although there are several minor
assumptions, critical model assumptions are provided as follows.
1. Lumped-parameter distribution assumes instantaneous equilibration between
tissue and blood and well-mixed distribution of the chemical within the interstitial
fluid.
2. Metabolism of chemicals by the cytochrome P-450 enzyme suite follows
Michaelis-Menten kinetics.
3. The release of acetylcholine from the pre-synaptic nerve cell and diffusion of the
neurotransmitters across the synaptic cleft occurs so rapidly that it is assumed to
be constant and continuous.
Parameters and Coefficients
Parameters and coefficients were either obtained from literature or fitted to the
model to produce results that mimicked observations presented in literature. All
parameters and coefficients used in the model are listed in Appendix B.
Diisopropylfluorophosphate (DFP) data were obtained from Gearhart and others. This
data were applied to the model to describe a typical organophosphate.
Very little pharmacokinetic data are available for atropine and oximes.
Application of partition coefficients and metabolic constants from DFP data to describe
the antidotes produced model results that generally mimicked limited observations of the
antidotes described in research literature. In addition, a kidney elimination constant of
0.35 for the antidotes produced reasonable elimination of the antidotes, in whole, from
the model with urine excretion.
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Synthesis rates and initial amounts of esterases were obtained from Gentry and
others. Degradation constants were calculated to maintain steady-state levels in each
tissue compartment.
Acetylcholine molecules were assumed to continuously occupy all binding sites
of acetylcholine esterases at a one-to-one molar ratio. Chemical reaction rate coefficients
were calculated to maintain this ratio under normal conditions.
Bartling and others provided some reaction rate coefficients between esterases
and organophosphates. It is known that butyrylcholinesterases have a higher affinity for
organophosphates than acetylcholine esterases, and acetylcholine esterases have a higher
affinity for organophosphates than carboxylesterases (Ashani and Pistinner 2004:365).
The organophosphate reaction rate with butyrylcholinesterases and carboxylesterases was
linked to the reaction rate with acetylcholine esterases. Butyrylcholinesterases were set to
be twice as reactive with organophosphates as compared to acetylcholine esterases.
Carboxylesterases were set to be half as reactive with organophosphates as compared to
acetylcholine esterases.
Ashani and Pistinner suggested that acetylcholine esterase levels at 65% of basal
levels were required to observe noticeable organophosphate induced symptoms, and
acetylcholine esterase levels at 10% of basal levels were critical to life sustaining
functions (Ashani and Pistinner 2004:365). In the model, an inhibition of acetylcholine
esterases to 65% of basal levels produced a symptom level of 1.09, and an inhibition of
acetylcholine esterases to 10% of basal levels produced a symptom level of 1.16. With no
inhibition of acetylcholine esterases, the standard symptom level was 1.0.
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Literature suggested that atropine doses of 10mg without organophosphate
poisoning also produced adverse symptoms (USAMRICD 2000:120). Application of 10
mg of atropine to the model produced a peak atropine level of 0.08 mg in the brain
compartment at 9 minutes and corresponded to a symptom level of 0.89. The symptom
level continued to decline to a low value of 0.45 at 97.8 minutes. It was assumed that
symptom levels below 0.91 produced adverse effects from atropine and symptom levels
below 0.84 for 10 minutes or longer produced death from atropine.
Sensitivity Testing
For sensitivity testing, 10 mg of organophosphate per liter of air was applied to
the model, beginning at time 0, for 15 minutes. In addition, 2 mg of atropine and 600 mg
of oxime were added at time 0. The maximum value of the symptom level was measured
and recorded. Each of the model parameters and coefficients was changed to a 50% and
150% value. The model was individually run for each change in parameters and
coefficients, and the maximum value of the symptom level was recorded.
The greatest variability of symptoms rested with the reaction rate coefficient
between acetylcholine esterases and the organophosphate. This result would show strong
support that variability of organophosphate toxicity among different types of
organophosphates rests greatest with the reaction rates between the organophosphates and
acetylcholine esterases. Of less variability, but noticeable, were the partition coefficients
of the organophosphate. As the partition coefficients of the organophosphate increased,
organophosphate persisted longer in the tissue compartments and reacted with more
acetylcholine esterases. In addition, the partition coefficients of atropine also had a
noticeable impact on symptom levels. As the partition coefficients of atropine increased,
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atropine persisted in the tissue compartments and countered the effects of excessive
neural stimulation for a longer period of time.
Although the partition coefficients of the organophosphate had an impact on the
symptom level, the DFP data provided by Gearhart and others was used as the standard
organophosphate, representing all varieties of organophosphorus chemicals.
Consequently, the major factors that would affect the differences in toxicity of
organophosphates in the model would result from the different reaction rate coefficients
with acetylcholine esterases.
Although the partition coefficients of atropine affected symptom levels, the
applied parameter values reasonably mirrored anecdotal observations of atropine.
Furthermore, there is no variability among a class of atropine as there is with
organophosphates. Therefore, maintaining atropine parameters at the values initially
suggested is reasonable and permits fair comparison among the tests.
Test Protocol
Initially, two types of theoretical organophosphates were created for the study.
The first organophosphate reacted rapidly with acetylcholine esterases, and the
organophosphate-acetylcholine esterase bonds matured quickly and responded poorly to
oximes. In comparison, the second organophosphate reacted slowly with acetylcholine
esterases, and organophosphate-acetylcholine esterase bonds matured slowly and
responded favorably to oximes.
A series of 19 tests were run for each organophosphate type. The tests are
described in Table 3 of Appendix C. Series A tests incorporated the more toxic
organophosphate and Series B tests incorporated the less toxic organophosphate. For each
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test, the time symptoms first appeared, the length of time symptoms persisted, and the
total amounts of antidotes administered were recorded. Each test applied an
organophosphate exposure of 5 mg per liter of air for 15 minutes beginning at +5
minutes.
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IV. Results and Analysis
Appendix C provides all test protocols and detailed results.
Series A and B Tests
The organophosphate exposure depressed acetylcholine levels and increased
symptom levels for both series of tests. Noticeable symptoms appeared at approximately
20 minutes for Series A tests and at 35 minutes for Series B tests after organophosphate
exposure began.
Increasing and decreasing rates of symptom levels at the end of 3 hours were
dependent on the amount of atropine in the tissue at that time. Therefore, it is expected
that all symptom levels will eventually return to higher levels beyond 3 hours until
acetylcholine esterase levels return to normal.
Atropine appeared to have immediate impacts on suppressing symptom levels. In
tests, where only atropine was used, symptom levels remained above noticeable levels for
only 1.2 to 8.4 minutes after the first injection of atropine.
In general, strictly time-based dosing strategies for atropine appear excessive and
wasteful. In both series, where only atropine was used, continuous interval dosing of
atropine led to a build-up of the antidote in the tissue and a prolonged level of critical
symptoms resulting from atropine toxicity. Conversely, it would seem that longer dosing
intervals between atropine administrations would risk the scenario of not administering
enough atropine to suppress organophosphate induced symptoms. In addition, after
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comparing the tests between the two series, the duration of symptom levels with the
presence of atropine varied with the organophosphate toxicity.
In just three hours, 56 to 72 mg of atropine were needed in a time-based dosing
strategy, which corresponds to 28 to 36 injections of atropine. A symptoms-based dosing
strategy for the same organophosphate exposures, required only 2 to 4 mg of atropine,
corresponding to 1 to 2 injections of atropine, to keep symptoms suppressed. The
symptoms-based dosing strategy required 1% to 3% of the total atropine used in the timebased dosing strategy and did not produce atropine toxicity.
Administering atropine before the onset of organophosphate exposure appears to
delay the onset of symptoms. In Series A, a pre-dose administration of atropine delayed
onset of symptoms by 69.2 minutes as compared to administering atropine upon the
appearance of noticeable symptoms. Similar results were found when comparing tests of
Series B.
Oxime treatment yielded poor results. In tests where only oximes were
administered, the oximes failed to suppress symptom levels. It is possible that the
organophosphates used in the tests were too toxic for the oximes to overcome.
There is a delay between the time organophosphate exposure begins and the first
observation of symptoms. Symptoms appeared nearly 20 minutes after the onset of
organophosphate exposure. This delay between exposure and symptoms results from the
fact that acetylcholine esterase levels must be degraded to 65% of basal levels before
symptoms first appear. The model was constructed to ensure oximes break
organophosphate-acetylcholine esterase bonds. However, oximes are at a severe time
disadvantage in performing their function when they are introduced at the onset of
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symptoms. A full 20 minutes would elapse between organophosphate exposure and
symptoms induced oxime injection. As a result, some organophosphate-acetylcholine
esterase bonds can mature before oximes ever have a chance to perform their function.
Atropine is at a similar disadvantage, but to a less severe degree. First atropine’s
therapeutic effect is not directly dependent on acetylcholine esterase levels. Second, as
noted earlier, atropine reacts quickly to suppress symptoms.
Another possibility for the failure of oximes may rest with the understood
mechanisms of organophosphate toxicity, and therefore, the structure of the model. The
model was created to allow organophosphates the ability to rebind with acetylcholine
esterases after the organophosphates were freed by oximes from initial bonds with
acetylcholine esterases. In this model structure, a mass of organophosphate and a mass of
acetylcholine esterase will bind together during a single time increment. For the next time
increment, some of the organophosphate-acetylcholine esterase mass ages and some of
the organophosphate-acetylcholine esterase mass is broken apart by the oxime. For the
third time increment, some of the freed acetylcholine esterases and organophosphates
immediately re-bind. This cycle repeats, and the oxime is in a losing battle since a portion
of the organophosphate-acetylcholine esterase mass ages with each time increment.
Series C Tests
To explore the possibility that a continuous cycle of binding and rebinding
between organophosphates and acetylcholine esterases mitigates or negates the effects of
oximes, the model was restructured so that freed organophosphates by oximes were
unable to rebind with acetylcholine esterases. Under this new model structure, the tests in
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Series B were repeated. The results for Series C tests were identical to the results of
Series B tests. Again, oximes were unable to suppress symptom levels.
Series D and E Tests
The inability of oximes to reduce symptom levels or the onset of symptoms was
disturbing. As a result, additional tests were undertaken to determine if the
organophosphate toxicity was too severe in comparison to the oxime therapeutic ability.
The new test protocols varied the reaction rate coefficients among the chemicals
and applied an organophosphate exposure and a time-based dosing strategy for oxime
treatment. Series D tests used the model structure in which freed organophosphates were
unable to reactivate with acetylcholine esterases once the organophosphates were freed
from bonds with the esterases by oximes. Series E tests used the model structure in which
freed organophosphates were able to reactivate with acetylcholine esterases once the
organophosphates were freed from bonds with the esterases by oximes.
Oximes show some efficacy in both test series when the aging rate of the
organophosphate-acetylcholine esterase bonds was significantly lowered. For Series D,
oximes reduced the destruction of acetylcholine esterases by nearly 11.5% as compared
to the same organophosphate exposure with no oxime dose. For series E, oximes reduced
the destruction of acetylcholine esterases by approximately 9.8% as compared to the
same organophosphate exposure with no oxime dose. These results suggest two findings.
First, oximes are slightly more effective if the organophosphates are unable to rebind
with acetylcholine esterases after the organophosphates are freed from bonds with the
esterases by oximes. Second, oxime efficacy is sensitive to the organophosphateacetylcholine esterase maturation rate coefficient.
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Series F Tests
For Series F tests, more attention was given to the maturation rate coefficients.
The maturation half-lives of some nerve agents are well known. Soman-acetylcholine
esterase bonds have an maturation half-life of less than 10 minutes, sarin-acetylcholine
esterase bonds have an maturation half-life of 5 hrs, and VX-acetylcholine esterase bonds
have an maturation half-life of approximately 48 hours (Cannard 2006:89).
Using equation (10), λ was calculated for half-lives of 10 minutes, 5 hours, and
48 hours. With equation (11), the maturation rate coefficients were then found through
model fitting.
Half-Life = .693/λ

(10)

A = Aoe-λt

(11)

Furthermore, the reaction rate coefficients between organophosphates and
acetylcholine esterases were refined based on literature data. Thiermann and others
present reaction rate coefficients of 132,000 mmol-1hr-1 and 1320 mmol-1hr-1 for two
organophosphorus insecticides (Thiermann and others, 1999:234). Bartling and others
provide reaction rate coefficients for some nerve agents ranging between 660,000
mmol-1hr-1 and 31,800,000 mmol-1hr-1 (Bartling and others, 2007:169). Using the
calculated maturation rate coefficients and using the reaction rate coefficients between
organophosphates and acetylcholine esterases of 1,000,000 mmol-1hr-1 and 50,000
mmol-1hr-1, organophosphates and oximes were applied to the model.
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There were four significant findings from this series of tests. First, when the
amount of organophosphates and time of organophosphate exposure is increased, the
efficacy of oximes is reduced. Second, when oximes are administered before
organophosphate exposure begins, more acetylcholine esterases are recovered over time.
Third, oximes appear to have no positive effect on suppressing symptoms when the
reaction rate between organophosphates and acetylcholine esterases is relatively high and
the maturation half-life of organophosphate-acetylcholine esterase bonds is also high.
Finally, in certain conditions, oximes appear to make acetylcholine esterase levels lower
and symptom levels higher than if no oximes were administered at all.
The last finding is illustrated in Figure 8. Figure 8 depicts the test in which 5 mg /
L of organophosphate was applied for 15 minutes from time +5 to time +20 minutes. In
this test, the reaction rate coefficient between organophosphates and acetylcholine
esterases was relatively high and the maturation half-life of organophosphateacetylcholine esterase bonds was 5 hours. An oxime injection of 600 mg was
administered upon the first appearance of noticeable symptoms and 600 mg of oxime
were administered every 5 minutes thereafter. In this graph, acetylcholine esterase levels
immediately dropped with the presence of organophosphate exposure. With the
administration of oximes, acetylcholine esterase levels dropped further and then began to
improve.
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Figure 8. Organophosphate Exposure with Continuous Oxime Treatment
When only one injection of 600 mg of oximes was administered at the appearance
of noticeable symptoms, acetylcholine esterase levels dropped and failed to improve.
This scenario is illustrated in Figure 9 and suggests that oximes made organophosphate
poisoning worse.

Figure 9. Organophosphate Exposure with One Oxime Injection
One of the reasons why the oximes may make acetylcholine esterase levels worse
is the fact that the reaction rate coefficients between oximes and esterases vary. The
organophosphate’s affinity for esterases decreases, in order, with butyrylcholinesterases,
acetylcholine esterases, and carboxylesterases. There is a potential that the oxime is
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breaking organophosphate-esterase bonds, and that a higher proportion of
organophosphates, originally bound to carboxylesterases, are now binding with
butyrylcholinesterases and acetylcholine esterases. If this mechanism is true,
carboxylesterase levels should increase with time after the injection of oximes. Figure 10
shows the esterase levels for the same organophosphate exposure and one injection of
600 mg of oxime. All three esterase levels decrease to lower levels after the injection of
oxime. Therefore, although organophosphates released from bonds with
carboxylesterases may be disproportionately rebinding with acetylcholine esterases and
butyrylcholinesterases, it is not the determining cause of lower acetylcholine esterase
levels.

Figure 10. Esterase Levels in Brain Compartment
Figure 11 shows carboxylesterase levels in other tissue compartments of the
model. As with Figure 10, carboxylesterase levels are decreasing after the injection of
oximes.
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Figure 11. Carboxylesterase Levels in Various Tissue Compartments
Figure 12 shows esterase levels in the arterial compartment. The figure shows that
all esterase levels improve after the oxime injection. Therefore, it appears that oximes are
effectively breaking organophosphate-enzyme bonds in the arterial compartment and
restoring some levels of these esterases. However, the released organophosphate is
diffusing into the other tissue compartments and lowering esterase levels in those
compartments.

Figure 12. Esterase Levels in Arterial Compartment
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The phenomenon that oximes may make organophosphates poisoning worse
results from physiology and the model structure. Organophosphates enter the model
through the lung compartment, proceed through the arterial compartment, and then pass
through tissue compartments. Esterases in the arterial compartment are the first to react
with and most severely affected by organophosphates.
This reasoning was explored by Ashani and Pistinner in 2003. In their study, the
researchers used exogenous butyrylcholinesterases as a prophylactic against
organophosphate poisoning. The researchers believed that since butyrylcholinesterases
have a higher affinity to organophosphates, excess butyrylcholinesterase levels in the
blood would react in greater numbers with organophosphates. As a result, fewer
organophosphates would react with acetylcholine esterases in the blood and fewer
organophosphates were able to diffuse into the tissue compartments. (Ashani and
Pistinner, 2003:358-367)
This same reasoning may explain why oximes are causing acetylcholine esterase
levels to drop to lower levels in the tissue compartment. Organophosphate-esterase bonds
in the blood are the first benefited by oximes. The oximes are improving esterase levels
in the blood, but freed organophosphates are diffusing into tissue compartments and
reacting with esterases in these tissue compartments.
Research literature supports this finding. In a 2007 article, Szinicz and others
reviewed the efficacy of oxime treatment. The authors stated “human reports of severe
toxicity frequently mention failure of oxime therapy and conclude oximes to be
ineffective, or even harmful” (Szinicz and others, 2007:25). Furthermore, citing other
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studies, the authors note that “disappointing results were found when … oxime
administration was discontinued prematurely” (Szinicz and others, 2007:27).
Szinicz and other suggested that the failure of oximes may result from freed
esterases rebinding with persisting organophosphates in the body (Szinicz and others,
2007:26). This suggested mechanism may complement the causes of oxime failure.
However, the model suggests that there are three determining and interdependent causes
of oxime failure for highly toxic organophosphates. First, the antidote disproportionately
breaks more organophosphate-esterase bonds in the blood as compared to
organophosphate-esterase bonds the tissue groups. Second, the freed organophosphates in
the blood are rebinding in greater numbers with esterases in the tissue groups. Finally, the
oxime reaction rate to break organophosphate-esterase bonds and the time elimination of
oximes from the body cannot overcome the affinity of organophosphates for esterases.
Although laboratory procedures to measure organophosphates poisoning and
acetylcholine esterase levels were not included in the scope of this study, the model
suggested interesting findings that may be relevant for these procedures. Scientists and
medical doctors typically measure acetylcholine esterase levels in the blood to determine
the severity of organophosphate poisoning and the efficacy of oximes. The model
suggests that this measurement technique may provide misleading results. The oxime
may be improving esterase levels in the blood while simultaneously lowering esterase
levels in tissue groups, where acetylcholine esterases are more critical to proper
physiological functioning.
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V. Discussion
Research Objectives
This research set out to accomplish four objectives.
1. Construct a physiologically based pharmacokinetic model (PBPK) to predict the tissue
concentrations of organophosphates, atropine, oximes, and pertinent biological
chemicals.
Although very little data are available to accurately predict tissue concentrations
for atropine and oxime, model fitting the parameters reasonably represented literature
observations. In addition, the partition coefficients and metabolic constants were
available for only a few organophosphates. A sensitivity test revealed that the parameters
for all of these chemicals had little impact on the outcome of human response. Research
revealing more accurate constants would likely produce more refined results. Such
refinement, however, given the results of the sensitivity analysis, would not be expected
to alter the conclusions of this work.
The PBPK model could incorporate two additional elements of organophosphate
poisoning that may provide beneficial information. First, the entry routes of
organophosphates could include ingestion and dermal absorption. Second, the toxic
effects of some organophosphates, such as parathion, result from the metabolite of the
chemical and not the chemical itself. Modeling these intake routes and metabolites would
likely alter time distribution of the chemical and the severity and onset of symptoms.
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2. Integrate the reactions among these chemicals into the model and produce a
quantitative measurement of their aggregate effects.
The equations to represent accumulation of acetylcholine molecules at the neural
synapse and symptom levels appeared to produce results that followed observed
outcomes of organophosphate poisoning. The equations were simple and allowed for easy
comparison among different organophosphate exposures and therapeutic strategies.
However, it is important to note that atropine and oximes mitigate different symptoms of
organophosphate poisoning, because the antidotes work at different types of neural
receptors. The tests conducted in this work included administering atropine and oximes
separately; and therefore, future refinement of the equations would not be expected to
alter the conclusions of this work.
The reactions among the chemicals appear to have had the most dominant affect
on the outcome of acetylcholine esterase and symptom levels. Applying the entire variety
of kinetic reaction rate constants will likely help to refine the efficacy of oximes in
relation to the various organophosphates. However, as with the chemical parameters,
such refinement would not be expected to alter the major conclusions of this work.
3. Apply therapeutic strategies for atropine and oximes against an organophosphate
exposure to the model.
This thesis reviewed time-based dosing of antidotes, symptoms-based dosing of
antidotes, administering antidotes upon the appearance of symptoms, and administering
antidotes before the onset of organophosphate exposure. Symptoms-based dosing of
atropine proved most economical and ensured correct amounts of the antidote were
administered to properly treat organophosphate poisoning and prevent adverse effects of
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atropine toxicity. Although agencies may find it easier to mass educate a time-based
dosing strategy for atropine, allocating resources to educate medical technicians and
military personnel about the intricacies of organophosphate induced symptoms may
better serve the patient and conserve the medication.
In certain scenarios, when oximes were effective, a time-based dosing strategy of
oximes proved most prudent. There is a delay between the time organophosphates bind to
acetylcholine esterases and the appearance of symptoms. During this time delay, some
organophosphate-acetylcholine esterase bonds begin to mature. It is imperative that
oximes are introduced early and maintain presence in the tissue groups until
organophosphates are completely removed from the body. A time-based application of
oximes would maintain oxime levels between an ideal range in the tissue groups.
Personnel at medical facilities could ensure the ideal range of oxime levels in the tissue
groups persisted until the removal of all organophosphates from the body.
Current procedures for medical facilities to administer antidotes are slightly
different than procedures for first care responders. Medical facilities have the ability to
administer the antidotes intravenously, normally have greater quantities of the antidotes,
and will potentially have to manage a patient for weeks until the full recovery of
acetylcholine esterases. It is possible the dynamics of organophosphate poisoning and the
optimal strategies for antidote administration are slightly different for long-term
treatment than what has been suggested in this study. Investigation into this long-term
treatment may be worthy for future research.
4. Compare model output and report significant differences among therapeutic strategies.
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Test results revealed five important findings. First, application of antidotes before
organophosphate exposure began tended to delay the onset and reduce the severity of
symptom levels. Although this finding is beneficial, the ability of individuals to anticipate
organophosphate exposure and preempt the poisoning with antidote treatment is highly
improbable.
Second, oxime efficacy decreases with the exposure duration and toxicity of
organophosphates. Although this may be an obvious and expected finding, the finding
does suggest that when the severity of organophosphate poisoning reaches a certain level,
oximes may no longer be effective in recovering any significant amounts of acetylcholine
esterases. This point was shown when an organophosphate with a kinetic reaction rate
constant similar to nerve agents and an aging half-life of 10 minutes was applied to the
model. Excessive oxime doses failed to recover any noticeable amounts of acetylcholine
esterases.
Third, oximes efficacy improves if organophosphates cannot reactivate with
acetylcholine esterases once the organophosphates are freed by oximes from the
esterases. The ability for organophosphates to rebind with acetylcholine esterases is
suspected but is not definitively known for all organophosphate types.
Fourth, there is a time delay between organophosphate exposure and the
appearance of noticeable symptoms. The time delay varies with the toxicity of the
organophosphate and the duration of organophosphate exposure. The time delay appears
to have no significant bearing on atropine efficacy. The benefits of atropine appear
largely independent of acetylcholine esterase levels and occur rather quickly. If oximes
are introduced when symptoms first appear, there is a potential that irreversible
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maturation of the organophosphate-acetylcholine esterase bond has already occurred. For
the condition when the aging half-life of organophosphate-acetylcholine esterase bonds is
relatively high, it is unlikely that copious doses of oximes will have any positive effect on
recovery of acetylcholine esterase and reducing symptom levels. However, oximes could
be significantly effective if oximes are introduced when symptoms first appear and if the
organophosphate-acetylcholine esterase aging rate coefficient is relatively low. Under
this condition, it is likely that oximes will help restore some, and possibly significant,
portions of acetylcholine esterase to a functional state.
Finally, under certain conditions, such as when the kinetic reaction rate
coefficient between organophosphates and acetylcholine esterases is relatively high and
the aging half-life of organophosphate-acetylcholine esterase bonds is moderate, oximes
depress acetylcholine esterase levels in tissue groups. The model suggests that oximes
effectively free organophosphate-enzyme bonds in the arterial compartment. However,
freed organophosphates diffuse into the other tissue groups, quickly react with esterases,
and cause esterase levels to decrease in those tissue groups. If continuous doses of
oximes are applied, acetylcholine esterase levels will eventually improve. However,
enough oxime must be continuously administered and the body must be able to tolerate
the large quantities of required oximes to achieve a positive effect.
Recommendations
There are two likely situations that involve organophosphate poisoning. First,
people living and working in rural, agricultural areas may become poisoned through
improper application and accidental exposure to organophosphorus insecticides. These
organophosphates tend to have low reaction rate coefficients with acetylcholine esterases
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and moderate to low aging half-lives of organophosphate-acetylcholine esterase bonds.
The model suggests that first care responders should administer atropine on a symptomsbased dosing strategy to ensure proper suppression of symptoms and limit adverse affects
of atropine toxicity. In addition, first care responders should administer oximes early and
continuously until further tests and time assure the complete removal of
organophosphates from the body. Oximes appear quite effective for relatively weak
organophosphates.
Organophosphate poisoning for people living in urban areas and military
personnel involved in conflicts will likely result from either a terrorist event or a military
weapon. It is highly probably that these organophosphates are of the nerve agent variety,
which have a high reaction rate coefficient with acetylcholine esterases. Again, the model
suggests that symptoms-based dosing of atropine is the most economical use of the
antidote. In addition to properly treating the patient, conservation of atropine could be
crucial when atropine supplies are limited. A terrorist event could involve mass casualties
and deployed military personnel only carry 6 mg of atropine on their persons.
Furthermore, the model suggests first care responders to a terrorist event or military
personnel in conflict should not administer oximes. It is likely that the oximes are not
effective, and in some cases, cause the severity of organophosphate toxicity to increase.
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Appendix A. Equations
Organophosphates
Slowly Perfused, Thigh Tissue, Diaphragm Tissue, and Fat Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P
Brain, Liver, Kidney, and Rapidly Perfused Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW /
NF)/(KM + CV / BW / NF)
Venous Compartment
dA/dt = E (CV) - QC * CV1 / P - (Vmax * CV1 / BW / NF)/(KM + CV1 /
BW / NF)
Lung Compartment
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1
Arterial Compartment
dA/dt = QC x CA1 - QC x CA / P - (Vmax * CV / BW / NF)/(KM + CV /
BW / NF)
Oxime
Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused, and Thigh Tissues
dA/dt = F * CA - F * QC * CV / BW / NF / P
Kidney Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P - EP * CV
Liver Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW /
NF)/(KM + CV / BW / NF)
Venous Compartment
dA/dt = E (CV) - QC * CV/ P
Lung Compartment
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1
Arterial Compartment
dA/dt = QC x CA1 - QC x CA / P
Atropine
Brain, Diaphragm, Fat, Richly Perfused, Slowly Perfused, and Thigh Tissues
dA/dt = F * CA - F * QC * CV / BW / NF / P
Kidney Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P - EP * CV
Liver Tissue
dA/dt = F * CA - F * QC * CV / BW / NF / P - (Vmax * CV / BW /
NF)/(KM + CV / BW / NF)
Venous Compartment
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dA/dt = E(CV) - QC * CV/ P
Lung Compartment
QP * Cexp + CV1 = QP * CA1 / P + QC * CA1
Arterial Compartment
dA/dt = QC x CA1 - QC x CA / P
Acetylcholinesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh
Tissues
dA/dt = X1 - X2A
Butyrylcholinesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh
Tissues
dA/dt = Y1 - Y2A
Carboxylesterase
Brain, Kidney, Diaphragm, Liver, Slowly Perfused, Richly Perfused, and Thigh
Tissues
dA/dt = Z1 - Z2A
Acetylcholinesterase and Organophosphate Chemical Reaction
L1
L3
AChE + OP <---> AChE/OP ---> Aged AChE/OP
L2
d[AChE/OP]/dt = L1 * [AChE] * [OP] – L2 [AChE/OP] – L3 [AChE/OP]
Butyrylcholinesterase and Organophosphate Chemical Reaction
M1
M3
BuChE + OP <---> BuChE/OP ---> Aged BuChE/OP
M2
d[BuChE]/dt = M1 * [BuChE] * [OP] – M2 * [BuChE/OP] – M3 *
[BuChE/OP]
Carboxylesterase and Organophosphate Chemical Reaction
N1
N3
CaE + OP <---> CaE/OP ---> Aged CaE/OP
N2
d[CaE/OP]/dt = N1 * [CaE] * [OP] – N2 [CaE/OP] – N3 [CaE/OP]
Oxime and AchE/OP Chemical Reaction
O1
AChE/OP + Oxime ---> AChE + OP + Oxime
-d[AChE/OP]/dt = O1 * [AChE/OP] * [Oxime]
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Oxime and BuChE/OP Chemical Reaction
P1
BuChE/OP + Oxime ---> BuChE + OP + Oxime
-d[BuChE/OP]/dt = P1 * [BuChE/OP] * [Oxime]
Oxime and CaE/OP Chemical Reaction
R1
CaE/OP + Oxime ---> CaE + OP + Oxime
-d[CaE/OP]/dt = R1 * [CaE/OP] * [Oxime]
Atropine, Acetylcholine, and Acetylcholine Esterase Reaction
d[ACh-AChE]/dt = p1{p1/( p1 + [Atropine])} - p2[AChE][ACh-AChE]
Symptoms
dSymptoms/dt = [ACh-AChE site]/[Basal ACh-AChE site]
Legend
dA/dt = change in chemical accumulation with respect to time (mass / time)
F = Fraction of blood flow that enters the tissue (unitless)
CA = Arterial Blood Outflow (mass / time)
QC = Cardiac Output (volume / time)
CV = Mass of OP in tissue (mass)
BW = Body Weight (mass)
NF = Normalization Factor (volume of tissue / mass of body weight)
P = Tissue to blood partition coefficient (unitless)
KM = Michaelis-Menten Constant (mass / volume)
Vmax = Maximum metabolism rate of OP (mass / time)
CA1 = arterial concentration (mass / volume)
QP = pulmonary ventilation rate (volume / time)
Cexp = concentration of chemical in alveolar space (mass / volume)
CV1 = venous blood output (mass / time)
P = air to blood partition coefficient (unitless)
QC = cardiac output (volume / time)
K = conversion factor to convert kg of air to L of air = 0.001204 kg of air / L of air
EP = Elimination parameter of pure oxime into urine. (time-1)
X1 = AChE synthesis rate (mass / time)
X2 = AChE degradation constant (time-1)
Y1 = BuChE synthesis rate (mass / time)
Y2 = BuChE degradation constant (time-1)
Z1 = CaE synthesis rate (mass / time)
Z2 = degradation constant (time-1)
p1 = Acetylcholine binding rate (mass / time)
p2 = Acetylcholine degradation constant (time-1)
O1 = Oxime reaction rate coefficient for AChE (mass-1time-1)
P1 = Oxime reaction rate coefficient for BuChE (mass-1time-1)
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R1 = Oxime reaction rate coefficient for CaE (mass-1time-1)
L1 = OP reaction rate coefficient with AChE (mass-1time-1)
L2 = OP-AChE natural separation coefficient (time-1)
L3 = OP-AChE aging coefficient (time-1)
M1 = OP reaction rate coefficient with BuChE (mass-1time-1)
M2 = OP-BuChE natural separation coefficient (time-1)
M3 = OP-BuChE aging coefficient (time-1)
N1 = OP reaction rate coefficient with CaE (mass-1time-1)
N2 = OP-CaE natural separation coefficient (time-1)
N3 = OP-CaE aging coefficient (time-1)
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Appendix B. Parameters
Physiological Parameters
Body Weight
Cardiac Output
Pulmonary Rate
Blood Flow to Tissue Fractions
Arterial
Brain
Diaphragm
Richly Perfused
Fat
Slowly Perfused
Thigh
Kidney
Liver
Venous
Tissue Normalization Factors
Arterial
Brain
Diaphragm
Richly Perfused
Fat
Slowly Perfused
Thigh
Kidney
Liver
Venous
Organophosphate
Molecular Weight
Partition Coefficients
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Arterial

60.9 kg
302 L/hr
354 L/hr

Gearhart et. al.
Gearhart et. al.
Gearhart et. al.

1
0.134
0.006
0.2
0.036
0.1244
0.0066
0.223
0.27
1

Assumed
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Assumed

0.02 L/kg
0.0214 L/kg
0.003 L/kg
0.0343 L/kg
0.17 L/kg
0.5238 L/kg
0.0276 L/kg
0.0043 L/kg
0.04 L/kg
0.057 L/kg

Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.

184 mg/mmol

Calculated

0.67
0.77
0.67
17.6
0.77
0.77
1.63
1.53
1

Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Assumed
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Venous
1
Blood/Air
12.57
Metabolic Parameters by A Esterases
Brain Vmax
688 mg/hr
Brain KM
440 mg/L
RPT Vmax
560 mg/hr
RPT KM
51 mg/L
Kidney Vmax
5042 mg/hr
Kidney KM
134 mg/L
Liver Vmax
52474 mg/hr
Liver KM
237 mg/L
Venous Vmax
616 mg/hr
Venous KM
199 mg/L
Arterial Vmax
216 mg/hr
Arterial KM
199 mg/L
Oxime
Molecular Weight
Partition Coefficients
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Arterial
Blood/Air
Metabolic Parameters
Liver Vmax
Liver KM
Kidney Partition Parameter
Elimination Partition
Atropine
Molecular Weight
Partition Coefficients
Bain
Diaphragm
RPT
Fat
SPT
Thigh

Assumed
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.
Gearhart et. al.

132 mg/mmol

Heath and McKeown

0.67
0.77
0.67
17.6
0.77
0.77
1.63
1.53
1
1
0

Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
Assumed

52474 mg/hr
237 mg/L

Assumed
Assumed

0.35

Assumed

289 mg/mmol

Heath and McKeown

0.67
0.77
0.67
17.6
0.77
0.77

Assumed
Assumed
Assumed
Assumed
Assumed
Assumed
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Kidney
Liver
Venous
Arterial
Blood/Air
Metabolic Parameters
Liver Vmax
Liver KM
Kidney Partition Parameter
Elimination Partition
Acetylcholinesterase
Molecular Weight
Synthesis Rate, X1
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Initial Concentration
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Degradation Constant, X2
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver

1.63
1.53
1
1
0

Assumed
Assumed
Assumed
Assumed
Assumed

52474 mg/hr
237 mg/L

Assumed
Assumed

0.35

Assumed

320 mmol/mg

Assumed

0.0001 umol/hr
0.00002 umol/hr
0.000003 umol/hr
0.00003 umol/hr
0.0 umol/hr
0.0005 umol/hr
0.00002 umol/hr
0.000004 umol/hr
0.00004 umol/hr
0.0001 umol/hr

Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.

0.001212 umol
0.04928 umol
0.000909 umol
0.008314 umol
0.0 umol
0.222196 umol
0.011708 umol
0.000104 umol
0.002424 umol
0.003454 umol

Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.

0.082508251 hr-1
Calculated
-1
Calculated
0.000405844 hr
Calculated
0.00330033 hr-1
-1
0.003608371 hr
Calculated
0.0 hr-1
Calculated
0.002250266 hr-1
Calculated
Calculated
0.001708234 hr-1
-1
Calculated
0.038461538 hr
0.01650165 hr-1
Calculated
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Venous
Butyrylcholinesterase
Molecular Weight
Synthesis Rate, Y1
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Initial Concentration
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Degradation Constant, Y2
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Carboxylesterase
Molecular Weight
Synthesis Rate, Z1
Arterial
Brain
Diaphragm
RPT

0.02895194 hr-1

Calculated

83.3 mmol/mg

Ashani and Pistinner

0.0001 umol/hr
0.00002 umol/hr
0.000003 umol/hr
0.00003 umol/hr
0.0 umol/hr
0.0005 umol/hr
0.00002 umol/hr
0.000004 umol/hr
0.00004 umol/hr
0.0001 umol/hr

Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.

0.00606 umol
0.016859 umol
0.002 umol
0.006236 umol
0.0 umol
0.190454 umol
0.010035 umol
0.000782 umol
0.019392 umol
0.017271 umol

Gentry et. al.
Gentry et. al.
Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.

0.01650165 hr-1
0.00118631 hr-1
0.0015 hr-1
0.004810776 hr-1
0.0 hr-1
0.002625306 hr-1
0.001993034 hr-1
0.00511509 hr-1
0.002062706 hr-1
0.005790053 hr-1

Calculated
Calculated
Calculated
Calculated
Calculated
Calculated
Calculated
Calculated
Calculated
Calculated

320 mg/mmol

Assumed

0.0001 umol/hr
0.00002 umol/hr
0.000003 umol/hr
0.00003 umol/hr

Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
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Fat
SPT
Thigh
Kidney
Liver
Venous
Initial Concentration
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Degradation Constant, Z2
Arterial
Brain
Diaphragm
RPT
Fat
SPT
Thigh
Kidney
Liver
Venous
Acetylcholine
Molecular Weight

0.0 umol/hr
0.0005 umol/hr
0.00002 umol/hr
0.000004 umol/hr
0.00004 umol/hr
0.0001 umol/hr

Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.

5.0904 umol
0.778104 umol
0.52722 umol
442.73754 umol
0.0 umol
73.007244 umol
3.846888 umol
4.29957 umol
110.292 umol
14.50764 umol

Gentry et. al.
Gentry et. al.
Gentry et. al.
Scaled from Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.
Gentry et. al.

1.96448 * 10-5 hr-1 Calculated
2.57035 * 10-5 hr-1 Calculated
5.69022 * 10-6 hr-1 Calculated
6.77602 * 10-8 hr-1 Calculated
0.0 hr-1
Calculated
6.848864 * 10-6 hr-1 Calculated
5.19901 * 10-6 hr-1 Calculated
9.30326 * 10-7 hr-1 Calculated
3.626674 * 10-7 hr-1 Calculated
6.89292 * 10-6 hr-1 Calculated

146 mg/mmol
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Appendix C. Test Protocols and Results
Table 3. Series A, B, and C Test Protocols
Test No.
Time-based dosing of antidotes
1
2 mg of atropine and 600 mg of oximes every 5 minutes starting when symptoms equal to
1.09
2
2 mg of atropine every 5 minutes starting when symptoms equal to 1.09
3
600 mg of oximes every 5 minutes starting when symptoms equal to 1.09
Symptoms-based dosing of antidotes
4
2 mg of atropine and 600 mg of oximes every time symptoms reach 1.09*
5
2 mg of atropine every time symptoms reach 1.09*
6
600 mg of oximes every time symptoms reach 1.09*
Higher initial dose of antidotes; followed by time-based dosing of antidotes
7
6 mg of atropine and 1800 mg of oximes when symptoms reach 1.09; additional 2 mg of
atropine and 600 mg of oximes every 5 minutes
8
6 mg of atropine when symptoms reach 1.09; additional 2 mg of atropine every 5 minutes
9
1800 mg of oximes when symptoms reach 1.09; additional 600 mg of oxime every 5 minutes
Higher initial dose of antidotes; followed by symptoms-based dosing of antidotes
10
6 mg of atropine and 1800 mg of oximes when symptoms reach 1.09; additional 2 mg of
atropine and 600 mg of oximes every time symptoms reach 1.09*
11
6 mg of atropine when symptoms reach 1.09; additional 2 mg of atropine every time
symptoms reach 1.09*
12
1800 mg of oximes when symptoms reach 1.09; additional 600 mg of oximes every time
symptoms reach 1.09*
Pretreatment of antidotes by 5 minutes; followed by time-based doses of antidotes
13
2 mg of atropine and 600 mg of oximes 5 minutes before organophosphate exposure begins
and repeated every 5 minutes
14
2 mg of atropine administered 5 minutes before organophosphate exposure begins and
repeated every 5 minutes
15
600 mg of oximes administered 5 minutes before organophosphate exposure begins and
repeated every 5 minutes.
Pretreatment of antidotes by 5 minutes; followed by symptoms-based doses of antidotes
16
2 mg of atropine and 600 mg of oximes 5 minutes before organophosphate exposure begins
and repeated every time symptoms reach 1.09*
17
2 mg of atropine 5 minutes before organophosphate exposure begins and repeated every time
symptoms reach 1.09*
18
600 mg of oximes administered 5 minutes before organophosphate exposure begins and
repeated every time symptoms reach 1.09*
Control
19
No administration of antidotes.
*not to exceed injections more frequent than 5 minute intervals
Reaction rate coefficients for Series A tests: L1 = 40,000; L2 = 100; L3 = 10,000; M1 = 80,000; M2 = 100;
M3 = 10,000; N1 = 20,000; N2 = 100; N3 = 10,000; O1 = P1 = R1 = 50
Reaction rate coefficients for Series B and C tests: L1 = 20,000; L2 = 50; L3 = 20,000; M1 = 40,000;
M2 = 50; M3 = 20,000; N1 = 10,000; N2 = 50; N3 = 10,000; O1 = P1 = R1 = 100

66

Test No.

First appearance of symptoms
(min)

Time at death (min)

Total amount of atropine
(mg)

Total amount of oximes (mg)

No. of atropine injections

No. of oxime injections

Total time symptoms > 1.09
(min)

Total time symptoms > 1.16
(min)

Total time symptoms < 0.91
(min)

Total time symptoms < 0.84
(min)

Symptom Levels at 3 hours

Symptoms trend at 3 hours

Table 4. Series A Test Results

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

25.2
25.2
25.2
25.2
25.2
25.2
25.2
25.2
25.2
25.2
25.2
25.2
12.6
12.6
25.8
92.4
94.4
25.2
25.2

88.2
87.6
45.6
N/A
N/A
45.6
80.4
80.4
45.6
108.0
108.0
45.6
36.0
36.0
45.6
N/A
N/A
45.6
45.6

62
62
0
4
4
0
66
66
0
6
6
0
72
72
0
4
4
0
0

18576
0
18576
1200
0
18576
19776
0
19776
18000
0
19776
21600
0
21600
1200
0
19200
0

31
31
0
2
2
0
31
31
0
1
1
0
36
36
0
2
2
0
0

31
0
31
2
0
31
31
0
31
1
0
31
36
0
36
2
0
32
0

8.4
8.4
154.8
8.4
0
0
144.6
0
154.8
2.4
2.4
154.8
0
0
154.8
4.2
4.2
154.8
154.8

0
0
144.6
0
0
144.6
0
0
144.6
0
0
144.6
0
0
144.6
0
0
144.6
144.6

114.0
114.0
0
0
0
0
121.8
121.8
0
90.6
90.6
0
167.4
167.4
0
0
0
0
0

102.0
102.0
0
0
0
0
109.2
109.2
0
15.0
15.0
0
154.2
154.2
0
0
0
0
0

0.43
0.43
1.72
0.98
0.98
1.72
0.41
0.41
1.72
0.99
0.99
1.72
0.33
0.33
1.72
0.97
0.97
1.72
1.72

Dec
Dec
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Inc
Inc
Inc
Dec
Dec
Inc
Inc
Inc
Inc
Inc
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Test No.

First appearance of symptoms
(min)

Time at death (min)

Total amount of atropine
(mg)

Total amount of oximes (mg)

No. of atropine injections

No. of oxime injections

Total time symptoms > 1.09
(min)

Total time symptoms > 1.16
(min)

Total time symptoms < 0.91
(min)

Total time symptoms < 0.84
(min)

Symptom Levels at 3 hours

Symptoms trend at 3 hours

Table 5. Series B and C Test Results

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

37.8
37.8
37.8
37.8
37.8
37.8
37.8
37.8
37.8
37.8
37.8
37.8
12.6
12.6
37.8
14.4
14.4
37.8
37.8

80.4
80.4
73.2
N/A
N/A
73.2
76.8
76.8
72.6
73.2
83.4
73.2
30.6
30.6
73.2
N/A
N/A
73.2
73.2

56
56
0
2
2
0
60
60
0
6
6
0
72
72
0
4
4
0
0

16800
0
16800
600
0
16800
18000
0
18000
18000
0
18000
21600
0
21600
1200
0
17400
0

28
28
0
1
1
0
28
28
0
1
1
0
36
36
0
2
2
0
0

28
0
28
1
0
28
28
0
28
1
0
28
36
0
36
2
0
28
0

2.4
2.4
142.2
2.4
2.4
142.2
1.2
1.2
142.2
1.2
1.2
142.2
0
0
142.2
1.2
1.8
142.2
136.2

0
0
117.0
0
0
117.0
0
0
117.0
0
0
117.0
0
0
117.0
0
0
117.0
117.0

117.6
117.6
0
0
0
0
113.4
113.4
0
106.8
106.8
0
167.4
167.4
0
81.6
81.6
0
0

109.8
109.8
0
0
0
0
113.4
113.4
0
106.8
106.8
0
159.6
159.6
0
0
0
0
0

0.30
0.30
1.31
1.04
1.04
1.31
0.28
0.28
1.31
0.80
0.80
1.31
0.21
0.21
1.31
1.06
1.06
1.31
1.31

Dec
Dec
Inc
Inc
Inc
Inc
Dec
Dec
Inc
Inc
Inc
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Inc
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Table 6. Series D and E Test Protocol
Test No.
1
2

L1
20000
20000

L2
50
50

L3
20000
20000

O1
100
100

3
4

20000
20000

50
50

20000
20000

500
500

5
6

20000
20000

50
50

5000
5000

100
100

7
5000
8
5000
9
20000
10
20000
M1 = 2 * L1
N1 = 0.5 * L1
L2 = M2 = N2
O1 = P1 = R1

50
50
50
50

5000
5000
100
100

7000
7000
2500
2500

Oxime Dose
No dose
600 mg of oxime every 5 min starting at time 0 and ending
after 30 min
No dose
600 mg of oxime every 5 min starting at time 0 and ending
after 30 min
No dose
600 mg of oxime every 5 min starting at time 0 and ending
after 30 min
No dose
2 doses of 600 mg of oxime at time 0 and at time 5 min
No dose
2 doses of 600 mg of oxime at time 0 and at time 5 min
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Test No.

First appearance of
symptoms (min)

Time at death (min)

Total amount of
oximes (mg)

No. of oxime
injections

Total time symptoms >
1.09 (min)

Total time symptoms >
1.16 (min)

Symptom levels at 3
hours

Symptoms trend at 3
hours

Min AChE levels (mg)

Time at min AChE
levels (min)

Table 7. Series D Test Results

1
2
3
4
5
6
7
8
9
10

37.8
37.8
37.8
37.8
37.8
37.8
N/A
N/A
48.0
154.2

73.2
73.2
73.2
73.8
73.8
73.8
N/A
N/A
103.2
N/A

0
3600
0
3600
0
3600
0
1200
0
1200

0
6
0
6
0
6
0
2
0
2

142.2
142.2
142.2
142.2
142.2
142.2
0
0
132
25.8

117
117
117
116.4
117.6
117.6
0
0
87
0

1.31
1.31
1.31
1.30
1.30
1.30
1.09
1.08
1.22
1.09

Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc

0.011677
0.011678
0.011677
0.011686
0.011696
0.011703
0.014369
0.014484
0.012662
0.014307

26.4
29.4
26.4
26.4
27.0
27.0
27.6
25.8
27.0
27.0

Test No.

First appearance of
symptoms (min)

Time at death (min)

Total amount of
oximes (mg)

No. of oxime
injections

Total time symptoms >
1.09 (min)

Total time symptoms >
1.16 (min)

Symptom levels at 3
hours

Symptoms trend at 3
hours

Min AChE levels (mg)

Time at min AChE
levels (min)

Table 8. Series E Test Results

1
2
3
4
5
6
7
8
9
10

37.8
37.8
37.8
37.8
37.8
37.8
N/A
N/A
48.0
102.6

73.2
73.2
73.2
73.8
73.8
73.8
N/A
N/A
103.2
N/A

0
3600
0
3600
0
3600
0
1200
0
1200

0
6
0
6
0
6
0
2
0
2

142.2
142.2
142.2
142.2
142.2
142.2
0
0
132.0
77.4

117
117
117
116.4
116.4
116.4
0
0
87.0
0

1.31
1.31
1.31
1.30
1.30
1.30
1.09
1.08
1.22
1.11

Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc
Inc

0.011677
0.011678
0.011677
0.011683
0.011690
0.011701
0.014369
0.014474
0.012662
0.014044

26.4
28.8
26.4
27.0
27.0
27.0
27.6
26.4
27.0
25.8
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Table 9. Series F Test Protocol
Fast OP reaction
Slow OP reaction
Fast aging
10 minute aging half-life
10 minute aging half-life
L1 = 1000000
L1 = 50000
L3 = 4.5
L3 = 4.5
Tests 1-3, 19-21
Tests 4-6, 22-24
Moderate aging
5 hour aging half-life
5 hour aging half-life
L1 = 1000000
L1 = 50000
L3 = 0.16
L3 = 0.16
Tests 7-9, 25-27
Tests 10-12, 28-30
Slow aging
48 hour aging half-life
48 our aging half-life
L1 = 1000000
L1 =50000
L3 = 0.014
L3 = 0.014
Tests 13-15, 31-33
Tests 16-18, 34-36
Each scenario consisted of 3 tests. For the first test, no oxime administration. For the second tests, 600 mg
of oxime repeated every 5 minutes, starting at noticeable symptoms. For the third test, 600 mg of
oxime repeated every 5 minutes, starting at time 0.
Tests 1 through 18 used an exposure of 5 mg of OP for 15 minutes starting at time +5 minutes
Tests 19 through 36 used an exposure of 10 mg of OP for 20 minutes starting at time +5 minutes
Oxime reaction rate coefficient set equal to 20
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Test No.

First appearance of
symptoms (min)

Time at death (min)

Total amount of
oxime (mg)

No of oxime
injections

Time symptoms
>1.09

Time symptoms >
1.16 (min)

Symptom levels at
3 hours

Symptoms trend at
3 hours

Min AChE level
(mg)

AChE level at 3
hours (mg)

Table 10. Series F Test Results

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

26.4
26.4
25.8
27.6
26.0
29.4
26.4
26.4
25.2
27.6
27.6
30.6
26.4
26.4
25.2
27.6
27.6
30.6
18.0
18.0
18.0
21.0
21.0
21.6
18.0
18.0
18.0
21.0
21.0
21.6
18.0
18.0
18.0
21.0
21.0
21.6

0.76
0.76
0.73
0.83
0.83
0.94
0.76
0.76
0.71
0.83
0.85
N/A
0.76
0.76
0.71
0.83
0.85
N/A
32.4
32.4
32.4
36.6
36.6
37.8
32.4
32.4
32.4
36.6
36.6
0.65
39.0
32.4
32.4
36.6
36.6
39.0

0
18000
21600
0
18000
21600
0
18000
21600
0
18000
21600
0
18000
21600
0
13200
21600
0
19200
21600
0
18000
21600
0
19200
21600
0
18000
21600
0
19200
21600
0
18000
21600

0
30
36
0
30
36
0
30
36
0
30
36
0
30
36
0
22
36
0
32
36
0
30
36
0
32
36
0
30
36
0
32
36
0
30
36

153.6
153.6
154.2
152.4
152.4
150.6
153.6
153.6
154.8
152.4
152.4
70.8
2.56
153.6
153.6
152.4
111.0
58.2
162.0
162.0
162.0
159.0
159.0
158.4
162.0
162.0
162.0
159.0
159.0
158.4
162.0
162.0
162.0
159.0
151.8
114.6

144.6
144.6
146.4
140.4
140.4
133.8
144.6
147.6
147.6
130.2
70.8
0
144.6
144.6
147.6
140.4
57.6
0
157.8
157.8
157.8
153.6
153.6
152.4
157.8
157.8
157.8
153.6
151.8
88.2
157.8
157.8
157.8
153.6
109.2
70.2

1.78
1.87
1.99
1.57
1.53
1.39
1.78
1.71
1.59
1.57
1.09
1.05
1.78
1.65
1.53
1.57
1.05
1.02
3.79
3.38
3.28
2.76
2.38
2.03
3.79
1.88
1.79
2.76
1.16
1.10
3.79
1.76
1.67
2.76
1.08
1.05

Inc
Inc
Inc
Inc
Inc
Inc
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Inc
Inc
Inc
Inc
Inc
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Dec
Dec
Inc
Dec
Dec

0.007683
0.007007
0.006309
0.009209
0.009209
0.009888
0.007683
0.005543
0.005585
0.009209
0.009209
0.010160
0.007683
0.005497
0.005563
0.009209
0.009209
0.010172
0.000001
0.000040
0.001334
0.002929
0.003193
0.004586
0.000001
0.000058
0.003070
0.002929
0.003374
0.005547
0.000001
0.000058
0.003158
0.002929
0.003382
0.005593

0.007691
0.007031
0.006375
0.009216
0.009607
0.010821
0.007691
0.010338
0.011114
0.009216
0.014967
0.015298
0.007691
0.011356
0.012229
0.009216
0.015695
0.015727
0.000016
0.001126
0.001411
0.002941
0.004518
0.006272
0.000016
0.010069
0.010504
0.002941
0.014468
0.014876
0.000016
0.011536
0.011970
0.002941
0.015650
0.015689
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